Literature DB >> 22289273

Immunohistochemical evaluation of AKT protein activation in canine mast cell tumours.

S Rodriguez1, K Fadlalla, T Graham, B Tameru, C D Fermin, T Samuel.   

Abstract

The pathogenesis of canine mast cell tumour (MCT) remains unknown. Moreover, therapeutic options are limited and resistance to targeted drugs and recurrences are common, necessitating the identification of additional cellular targets for therapy. In this study we investigated the expression of phosphorylated AKT protein in 25 archival canine MCT samples by immunohistochemistry and examined the correlation between the immunohistochemical scores and histopathological tumour grades. AKT protein was detected in all of the samples and 24 of the 25 samples expressed the phosphorylated form of the protein, albeit with variable intensity. However, when the immunohistochemical scores of weak, intermediate and strong labelling were compared with the histopathological grades I to III, there was no strong correlation. This study suggests that canine MCT cells have activated AKT and indicates the need for further research on the role of the AKT protein and the possibility of targeting the AKT signalling pathway in MCTs.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22289273      PMCID: PMC3341505          DOI: 10.1016/j.jcpa.2011.12.003

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  32 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

2.  Skin neoplasia in dogs.

Authors:  J W Finnie; D E Bostock
Journal:  Aust Vet J       Date:  1979-12       Impact factor: 1.281

Review 3.  Canine mast cell tumors.

Authors:  D A O'Keefe
Journal:  Vet Clin North Am Small Anim Pract       Date:  1990-07       Impact factor: 2.093

4.  KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.

Authors:  Karoline V Gleixner; Matthias Mayerhofer; Sabine Cerny-Reiterer; Gregor Hörmann; Uwe Rix; Keiryn L Bennett; Emir Hadzijusufovic; Renata A Meyer; Winfried F Pickl; Jason Gotlib; Hans-Peter Horny; Andreas Reiter; Gerlinde Mitterbauer-Hohendanner; Giulio Superti-Furga; Peter Valent
Journal:  Blood       Date:  2011-06-16       Impact factor: 22.113

Review 5.  The biology of Kit in disease and the application of pharmacogenetics.

Authors:  Cem Akin; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2004-07       Impact factor: 10.793

Review 6.  Mast cell tumors in the dog.

Authors:  Cheryl A London; Bernard Seguin
Journal:  Vet Clin North Am Small Anim Pract       Date:  2003-05       Impact factor: 2.093

7.  Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis.

Authors:  Cameron L R Jones; Robert A Grahn; May B Chien; Leslie A Lyons; Cheryl A London
Journal:  J Vet Diagn Invest       Date:  2004-03       Impact factor: 1.279

8.  Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs.

Authors:  Sue Downing; May B Chien; Philip H Kass; Peter E Moore; Cheryl A London
Journal:  Am J Vet Res       Date:  2002-12       Impact factor: 1.156

9.  Nucleolar organiser regions as indicators of post-surgical prognosis in canine spontaneous mast cell tumours.

Authors:  D E Bostock; J Crocker; K Harris; P Smith
Journal:  Br J Cancer       Date:  1989-06       Impact factor: 7.640

10.  Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells.

Authors:  H Serve; N S Yee; G Stella; L Sepp-Lorenzino; J C Tan; P Besmer
Journal:  EMBO J       Date:  1995-02-01       Impact factor: 11.598

View more
  3 in total

1.  An Immunohistochemical Study of the PTEN/AKT Pathway Involvement in Canine and Feline Mammary Tumors.

Authors:  Pietro Asproni; Francesca Millanta; Lorenzo Ressel; Fabio Podestà; Francesca Parisi; Iacopo Vannozzi; Alessandro Poli
Journal:  Animals (Basel)       Date:  2021-02-01       Impact factor: 2.752

2.  Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells.

Authors:  Yusuke Murase; Kenji Hosoya; Takachika Sato; Sangho Kim; Masahiro Okumura
Journal:  Oncol Rep       Date:  2022-01-28       Impact factor: 3.906

Review 3.  Oncolytic Viruses for Canine Cancer Treatment.

Authors:  Diana Sánchez; Gabriela Cesarman-Maus; Alfredo Amador-Molina; Marcela Lizano
Journal:  Cancers (Basel)       Date:  2018-10-27       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.